Free Newsletter
LigoCyte rounds up $28M in third round
Bozeman, MT-based LigoCyte Pharmaceuticals has rounded up $28 million in its third round of venture capital. The money will be used for the clinical development of two lead vaccines targeting norovirus and influenza. Forward Ventures, JAFCO, and Novartis Venture Fund led the round with Fidelity Biosciences and MedImmune Ventures participating. The norovirus vaccine is currently finishing a Phase I trial. LigoCyte also plans to advance its influenza vaccine into human trials. The company uses virus-like particle and monoclonal antibody technology.
"We are especially pleased with the mix of institutional and strategic investors in this Series C round of financing," said LigoCyte CEO Donald Beeman. "These resources will fund LigoCyte through critical proof of principle of our later-stage development candidates."
- read the press release on the latest round
Related Article:
LigoCyte forges deal with Biogen Idec. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
